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ABSTRACT
Recent data indicate that tumor-associated neutrophils (TANs) serve a dual role 
in tumor progression and regression. CD66b is a neutrophil marker and has been 
associated with patient outcome in various cancers. However, its clinical impact in 
non-small cell lung cancer (NSCLC) remains controversial. 536 NSCLC patients, of 
which 172 harbored lymph node metastases, were included in this study. Tissue 
microarrays were constructed and multiplexed immunohistochemistry of CD66b, CD34 
and pan-keratin was performed to evaluate the localization and quantity of CD66b+ 
TANs. High intratumoral CD66b+ TANs density in squamous cell carcinoma (SCC) 
subgroup was an independent positive prognosticator for disease-specific survival 
(P = 0.038). In contrast, high intratumoral TANs density was an independent negative 
prognostic factor in the adenocarcinoma (ADC) subgroup (P= 0.032). Likewise, in ADC 
patients with lymph node metastases, high level of intratumoral TANs was associated 
with poor prognosis (P = 0.003). Stromal CD66b+ TANs were not associated with 
outcome of NSCLC patients. In conclusion, CD66b+ TANs show diverging prognostic 
effect in NSCLC patients according to histological subgroups. The presence of CD66b+ 
TANs could prove pivotal for development of an immunoscore in ADC NSCLC patients.
INTRODUCTION
Lung cancer is the leading cause for cancer-related 
deaths worldwide [1]. Even after complete surgical 
resections, the prognosis of NSCLC patients remain poor 
due to locoregional relapses and/or metastases [2]. Huge 
efforts are being invested in identifying new prognostic 
and predictive molecular markers in order to improve 
treatment stratification and overall survival (OS).
Tumor infiltrating leukocytes (TILs) positively 
affect NSCLC patient outcomes [3]. Of these, a significant 
proportion constitute tumor-associated neutrophils (TANs) 
[4]. It has been hypothesized that TANs polarize into either 
a N1 antitumoral or N2 protumoral phenotype in response 
to cancer epithelial- and stromal-derived signals [5, 6]. 
The protumoral functions of the N2 phenotype include 
increased angiogenesis [8], tumor cell proliferation [9], 
extracellular matrix remodelling, lymphangiogenesis 
and inhibition of the anti-tumoral immune response [10]. 
The anti-tumoral activity of the N1 phenotype comprises 
immune-surveillance including cytotoxicity towards 
cancer cells. The cellular cytotoxicity leads to recruitment 
and activation of cells related to both the innate and 
adaptive immune systems [11, 12].
CD66b is an established marker of TANs [13], 
stored in neutrophil granules and constitutively expressed 
by human neutrophils [14]. In contrast to the cells of 
adaptive immune system, the prognostic role of CD66b+ 
TANs has been associated with unfavorable outcome for 
a number of malignancies [15–18], whereas improved 
survival has been reported for gastric and colorectal 
carcinoma [19, 20]. In NSCLC, two previous studies 
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failed to reveal significant associations between TANs 
and patients outcome [21, 22], neither of these studies 
evaluated histological subtypes.
Differential outcome of CD66b+ TAN presence 
according to histological subtypes could be expected since 
squamous cell carcinoma (SCC) and adenocarcinoma 
(ADC) are recognized as different diseases regarding 
biology, treatment stratification and efficacy [23]. This 
harmonizes with our previous studies on the immune 
contexture in SCC vs ADC NSCLC patients [24].
Herein, we 1) investigate the prognostic role of 
CD66b+ TANs in primary tumors of NSCLC patients 
stratified into SCC and ADC subgroups, 2) assess the 
prognostic effect of intraepithelial CD66b+ TANs in 
metastatic lymph nodes from N+ patients and 3) correlate 
the presence of CD66b+ TANs with 104 tumor molecular 
markers previously evaluated in this same cohort.
RESULTS
Patient characteristics
A retrospectively registered cohort of 536 patients 
with NSCLC, of which 172 had LN metastases at the 
time of diagnosis, was investigated for CD66b+ TAN 
density. Detailed information of the cohort has previously 
been published [24, 25]. The average age of the patients 
at the time of surgery was 67 years old (range, 28- 
85), and 68% of the patients were men. According to 
histology, primary tumors were divided into the following 
histotypes: 289 squamous cell carcinomas (SCC), 201 
adenocarcinomas (ADC) and 46 large-cell carcinomas 
(LCC). Histological features in the LN+ cohort were: 91 
(53%) patients SCC, 68 (40%) patients ADC and 13 (8%) 
patients undifferentiated carcinomas (NOS). During the 
period 2005-2010, 43 (20%) patients received adjuvant 
chemotherapy. 76 (14%) patients received adjuvant 
radiotherapy.
Interobserver variability
The intraclass correlation coefficients (ICCs) and 
Cohen’s Kappa for the CD66b scores were as follows: 
Intratumoral primary tumor (ICC = 0.94, P < 0.001, Kappa 
= 0.79, P < 0.001), stromal (ICC = 0.93, P < 0.001, Kappa 
= 0.75, P < 0.001) and intratumoral lymph node metastases 
(ICC = 0.95, P < 0.001, Kappa = 0.80, P < 0.001).
Expression and association of CD66b+ TANs with 
histopathological variables
CD66b was expressed on the membrane and in 
the cytoplasm of TANs, while multiplex IHC allowed 
effortless distinction between intratumoral, stromal and 
intra-vascular CD66+ TANs (Figure 1). Associations 
between CD66b+ TAN density and clinicopathological 
variables in the overall cohort (primary tumor, LN+) and 
within histological subtypes are presented in Table 1. 
Intratumoral CD66b+ TANs in the primary tumor were 
positively associated with increasing tStage (P = 0.011) 
and pStage IIB (P = 0.002) in the whole cohort, and was 
negatively associated with nStage (P = 0.032) in the SCC 
subgroup. Stromal CD66b+ cells were associated with 
weight loss in the whole cohort (P = 0.044) and in the 
SCC subgroup (P = 0.031). No associations between 
clinicopathological variables and the presence of CD66b+ 
TANs were observed in the ADC-group or in the N+ 
subgroups (Table 1).
Survival analyses
Tables 2 and 3 and Figure 2 summarize the 
intratumoral presence of CD66b+ cells in primary tumors 
and lymph node metastases and their role on diseases-
specific survival (DSS) in univariable and multivariable 
analyses. No significant effects on survival were observed 
in the overall cohort. In the SCC subgroup, the presence 
of intratumoral CD66b+ cells was an independent positive 
prognostic factor [univariate P = 0.038 (Figure 2B), 
multivariable P = 0.021, HR 0.59 (0.38-0.92)], while in the 
ADC subgroup, the presence of intratumoral CD66b+ cells 
was an independent adverse prognostic factor [univariate 
P = 0.032 (Figure 2C), multivariable P = 0.020, HR 1.7 
(1.1-2.65)]. In patients with nodal metastases (Figure 
2G–2I), the presence of intratumoral CD66b+ cells was 
an independent adverse prognostic factor for the ADC 
subgroup [univariate P = 0.003 (Figure 2I), multivariable 
P = 0.004, HR = 2.87 (1.39-5.91)]. Results were largely 
similar when assessing disease-free survival (DFS) and 
OS (Supplementary Figures S1 and S2). The density of 
CD66+ neutrophils in the stroma was not significantly 
associated with survival (Figure 2D–2F).
CD66b+ TANs and treatment interactions
The adjuvant chemotherapy treatment-TAN 
interaction was not significant for OS, DFS and DSS in 
either overall cohort or ADC and SCC subgroups (data 
not shown).
Further, for patients who received adjuvant 
radiotherapy, there was a tendency towards increased survival 
differences between patients with high vs low CD66b density. 
Although, similar tendencies were seen for patients who did 
not receive radiotherapy, and subgroup analysis should be 
interpreted with caution because of the small sample size 
[SCC: n=41; ADC: n=19] (data not shown).
Presence of CD66b+ neutrophils and their 
correlations with prognostic markers
Table 4 summarizes the significant correlations 
between the presence of CD66b+ cells and prognostic 
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Table 1: Correlations between clinicopathological variables and A) Intratumoral CD66b+ cells in resected primary 
tumors of NSCLC patients in the overall cohort and stratified into the SCC and ADC subgroups (chi-square test 
and fisher exact test, N = 536, 289 and 201 respectively); B) Intratumoral CD66b+ cells in lymph-node tissue from N+ 
NSCLC patients in the overall cohort and stratified into the SCC and ADC subgroups (chi-square test and fisher exact 
test, N = 172, 91 and 68 respectively)
A B
All SCC ADC All SCC ADC
Low High P Low High P Low High P Low High P Low High P Low High P
Age 0.535 0.223 0.023 1.000 0.284 0.367
 ≤65 129 85 65 38 54 39 41 17 22 6 18 10
 >65 187 108 96 79 71 24 42 17 18 11 17 5
Gender 0.221 0.158 0.522 0.130 0.706 0.069
 Female 92 67 35 35 48 28 28 6 8 2 17 3
 Male 224 126 126 82 77 35 55 28 32 15 18 12
ECOG 0.092 0.189 0.394 0.407 0.432 1.000
 0 185 113 88 65 75 42 48 15 22 6 20 9
 1 115 61 65 40 43 16 28 15 15 9 11 5
 2 16 19 8 12 7 5 7 4 3 2 4 1
Smoking 0.376 1.000 0.497 0.931 0.299 0.175
 Never 12 3 4 2 7 1 3 1 2 0 1 1
 Previous 200 124 101 74 77 40 49 21 25 8 20 12
 Present 104 66 54 41 41 22 31 12 13 9 14 2
Weight loss 0.061 0.183 1.000 0.195 0.058 0.654
 <10% 291 167 147 100 116 58 76 28 38 13 30 14
 ≥10% 25 25 14 17 9 5 7 6 2 4 5 1
Surgical 
procedure
1.000 0.276 0.867 0.703 1.000 0.746
 Wedge/
Lobectomy
229 140 103 83 100 49 44 16 16 7 24 9
 Pulmonectomy 87 53 58 34 25 14 39 18 24 10 11 6
Margins 0.357 0.031 1.000 0.131 0.428 0.152
 Free 286 180 138 110 118 60 75 27 35 13 33 12
 Not free 30 13 23 7 7 3 8 7 5 4 2 3
tStage 0.011 0.119 0.431 0.064 0.495 0.371
 IA 48 22 23 13 23 9 6 1 3 1 3 0
 IB 60 30 27 19 27 10 15 1 5 0 7 1
 IIA 120 58 57 30 50 23 31 13 15 6 15 7
 IIB 43 30 29 22 10 7 12 6 7 5 4 1
 III 42 50 23 32 14 13 15 13 7 5 6 6
 IV 3 3 2 1 1 1 4 0 3 0
nStage 0.072 0.032 0.607 0.584 0.315 1.000
 0 204 143 101 90 81 45
 1 76 36 46 23 27 10 55 25 30 15 21 9




All SCC ADC All SCC ADC
Low High P Low High P Low High P Low High P Low High P Low High P
pStage 0.002 0.061 0.070 0.229 0.386 0.548
 IA 81 47 36 30 39 17
 IB 70 44 32 23 28 16
 IIA 82 33 50 25 26 7 36 10 19 6 15 4
 IIB 30 41 19 27 8 12 6 5 4 4 2 1
 IIIA 53 28 24 12 24 11 41 19 17 7 18 10
Histology 0.096 0.908
 SCC 161 117 40 17
 ADC 125 63 35 15
 NOS 30 13 8 2
Differentiation 0.674 0.851 0.083 0.655 0.794 0.236
 Poor 132 84 58 40 44 31 41 20 15 7 18 11
 Moderate 143 89 87 63 56 26 37 13 22 10 15 3
 Well 41 20 16 14 25 6 5 1 3 0 2 1
Vascular 
infiltration
0.493 0.218 1.000 0.686 0.752 1.000
 No 253 161 124 98 106 54 58 25 27 13 27 11
 Yes 61 32 37 19 17 9 25 8 13 4 8 3
Abbreviations: SCC, squamous cell carcinoma; ADC, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified
(Continued )
Table 2: A) Intratumoral CD66b+ cells in the primary tumors of resected NSCLC patients as predictors of disease-
specific survival in the overall cohort and stratified into SCC and ADC subgroups (univariate analyses, log-rank test, 
N = 536, 289 and 201 respectively). B) Intratumoral CD66b+ cells in lymph-node tissue from N+ NSCLC patients as 
predictors of disease-specific survival in the overall cohort and stratified into SCC and ADC subgroups (univariate 
analyses, log-rank test, N = 172, 91 and 68 respectively)
All SCC ADC
A N(%) 5  
Year
Median HR  
(95%CI)
P N(%) 5 
Year
Median HR  
(95%CI)
P N(%) 5 
Year







 ≤5% 316(59) 56 104 1 161(56) 62 235 1 125(62) 50 71 1
 >5% 193(36) 60 NA 0.92 
(0.69-1.21)
117(40) 70 NA 0.64 
(0.43-0.96)
63(31) 43 47 1.57 
(1-2.46)





 ≤5% 83(48) 33 30 1 40(44) 45 35 1 35(51) 23 30 1
 >5% 34(20) 19 16 1.57 
(0.9-2.74)
17(19) 40 19 1.17 
(0.52-2.61)
15(22) 0 8 2.71 
(1.1-6.65)
 missing 55(32) 34(37) 18(26)
Abbreviations: SCC, squamous cell carcinoma; ADC, adenocarcinoma; LN+, metastatic lymph nodes
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markers previously studied in this cohort. Supplementary 
Table S1 includes all markers involved in the correlation 
analysis (n=104). After corrections for multiple testing, 
intratumoral CD66b+ cells in the whole cohort, were 
correlated with stromal CD66b+ (r = 0.76), CSF1R 
(r = 0.23), MCSF (r = 0.28), MCT1 (r = 0.23) and 
MCT4 (r = 0.22) and intratumoral CD68+ cells (r = 0.23). 
Stromal CD66b+ cells were correlated with intratumoral 
CD66b+ (r = 0.76) and stromal CSF1R (r = 0.25), CD68+ 
cells (r = 0.23), MCSF (r = 0.25) and MCT1 (r = 0.26). 
In the SCC subgroup, intratumoral CD66b+ cells were 
correlated with stromal expression of CD66b+ (r = 0.80) 
and MCSF (r = 0.32), while stromal CD66b+ cells were 
correlated with intratumoral CD66b+ (r = 0.80), CD68+ 
cells (r = 0.28), MCT4 (r = 0.27) and stromal CSF1R 
(r = 0.28), stromal CD68+ cells (r = 0.27), MCSF 
(r = 0.32), FOXO1A (r = 0.28) and MCT1 (r = 0.30). In 
the ADC subgroup intratumoral CD66b+ cells correlated 
only with stromal CD66b+ cells (r = 0.66).
DISCUSSION
In our large cohort of unselected stage I-IIIA NSCLC 
patients, we demonstrate that the presence of intratumoral 
CD66b+ neutrophils mediate opposing independent 
prognostic significance in the ADC versus SCC subtype. 
Moreover, this prognostic significance goes undetected 
when the role of TANs is investigated in the whole NSCLC 
cohort, and not according to histology. Lymph nodes from 
LN+ patients of the same cohort, when evaluated as a 
validation cohort, revealed similar prognostic harmony with 
their corresponding primary tumors.
CD66b is recognized as a TAN marker in several 
studies, and a recent meta-analysis reported the presence 
of CD66b+ TANs to be a significant unfavorable 
prognosticator in solid malignant tumors [26]. In NSCLC, 
the role of CD66b+ TANs remains controversial. Ilie et al. 
[22] found the CD66b+ TAN/CD8+ T cell ratio to predict 
recurrence and poor OS. In contrast Carus et al. [21] did not 
Figure 1: A. Scoring assessment guideline. Scoring of intratumoral (tumor nest) and stromal CD66b+ neutrophils was conducted 
utilizing the following exclusion- and inclusion-criteria. In intratumoral assessment, we have included only unaggregated CD66b+ cells 
completely surrounded by tumor epithelial cells. Stromal assessment only regarded extravascular CD66b+ cells. The excluded areas 
consisted of intratumoral and stromal aggregates of neutrophils, intravascular neutrophils and CD66b+ cells with granular background in 
stroma. Especially in SCC tissue, the central tumor zone often had dense granular CD66+ structures with some CD66b+ cells, considered 
a pre- or necrotic area, which were excluded from scoring. B. Multiplexed IHC analysis of TANs with CD66b/CD34/pan-CK panel, high 
versus low intratumoral densities. Brown, purple and yellow substrates were applied to visualize CD66b, CD34 and pan-CK respectively 
(magnification 10x, 20x).
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detect an association between CD66b+ TANs and survival. 
Nevertheless, studies in renal cell [15], head and neck [16], 
bronchioloalveolar [17] and oesophageal carcinoma [18] 
have demonstrated association between the presence of 
intratumoral CD66b+ neutrophils and poor prognosis, while 
in gastric and colorectal carcinoma high levels of CD66b+ 
neutrophils indicated a favorable prognosis [19, 20].
The current knowledge of TAN function is based 
on studies in tumor-bearing animal models, not in 
humans. Deletion or alteration of TGF-β signaling within 
the tumor lead to reduced tumor progression through the 
activation of CD8+ T cells and recruitment of myeloid-
derived suppressor cells (MDSCs) [27]. In a previous in 
vivo study, TGF- β signaling observed in tumor-bearing 
mice exerted effects on polymorphonuclear lineages 
of MDSCs and induced a distinct N2 TAN subtype, 
which promoted cancer development. Furthermore, 
abrogation of TGF- β signaling polarized TANs from 
Table 3: Multivariable models summarizing significant independent prognostic factors in A) The SCC and ADC 
subgroups of the total cohort (Cox regression analyses, N = 289 and 201 respectively) and B) The ADC subgroup of the 












P HR (95% 
CI)





 ≤5% 1.000 1.000 1.000








 IA 1.000 1.000




















 Moderate 0.91 (0.59-1.42) 0.682
 Well 0.44 (0.22-0.89) 0.022
ECOG
 0 1.000
 1 1.76 (1.13-2.74) 0.012
 2 2.93 (1.28-6.7) 0.011
Abbreviations: SCC, squamous cell carcinoma; ADC, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group
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the protumoral N2 to the antitumoral N1 phenotype. 
Depletion of antitumoral N1 TANs following TGF-β 
blockade reduced CD8+ T cells activation and promoted 
tumor growth [5]. In a mouse model, N1 TAN mediated 
activation of CD8+ T cells has been determined 
the main mechanism responsible for mediating an 
antitumoral response. It is tempting to infer that the 
same mechanisms are present in humans, but as with 
M1/M2 tissue macrophage differentiation, there are 
broad differences between tumor-bearing mice and 
humans. As macrophages and neutrophils ascend from a 
common progenitor, the complexity observed in human 
macrophage differentiation should be expected for 
neutrophils as well [28]. Not surprisingly, we observe 
Figure 2: Disease-specific survival curves for A. Intratumoral CD66b in the overall cohort (OC) of primary tumors (PT); B. 
Intratumoral CD66b in squamous cell carcinomas (SCC) of PT; C. Intratumoral CD66b in adenocarcinomas (ADC) of PT; D. Stromal 
CD66b in the overall cohort of PT; E. Stromal CD66b in SCC of PT; F. Stromal CD66b in ADC of PT; G. Intratumoral CD66b in the overall 
cohort of LN+; H. Intratumoral CD66b in SCC of LN+; I. Intratumoral CD66b in ADC of LN+
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Table 4: Significant Spearman rank-correlations with R-values > 0.20 between intratumoral and stromal CD66b+ 
TANs and tumor-associated markers in samples from NSCLC in the total cohort and in subgroups according to 
histology (Total cohort = 326, SCC = 191; ADC = 95)
ALL SCC ADC
Correlations with markers expressed in intratumoral cells
Tumor Stroma Tumor Stroma Tumor Stroma
CAIX 0.23* ANG T
CD34 -0.27** -0.27** ANG T
D240 0.21* ANG T
DLL4 -0.20*** -0.24* ANG T
FGFR1 -0.23* ANG T
Glut1 0.28** ANG T
NOTCH1 0.25* ANG T
NOTCH4 -0.22** ANG T
PHD-3 -0.33*** ANG T
Bad-cyt -0.24*** -0.21* -0.22* EMT T
Bad-Nuc -0.24** EMT T
Her3 -0.21** EMT T
Ki67 0.22* EMT T
pHer2 -0.22** EMT T
pi3K -0.21*** EMT T
CD66b 0.76# 0.80# 0.66# IMM T
CD68 0.23# 0.28*** 0.28# IMM T
MCT1 0.22* MET T
MCT4 0.22# 0.22** 0.27# MET T
PGC1-α -0.23* MET T
Correlations with markers expressed in tumor stroma
Tumor Stroma Tumor Stroma Tumor Stroma
Ang2 0.21* ANG S
D240 0.24* ANG S
DLL4 0.21** ANG S
miR21 0.21*** 0.23* ANG S
NOTCH4 0.21** ANG S
PDGF-A 0.22** 0.23** 0.23* ANG S
VEGF-A 0.22** ANG S
VEGF-D 0.21** 0.21* ANG S
cAkt 0.24*** EMT S
ERK3 0.20** EMT S
IGF1 0.21** EMT S
NfκB 0.23** EMT S
(Continued )
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a close correlation between CD66b+ TANs and CD68+ 
(pan-macrophage marker) expression in our cohort 
(Table 4) and the MDSC associated colony-stimulating 
factor-1 receptor, indicating a close relationship between 
TANs and macrophages in NSCLC.
The idea that human TANs may differentially 
affect the tumor-host immune activity based on stage 
and histological subtype of cancer is intriguing. In 
early stage NSCLC, TANs have been shown not to be 
mainly immunosuppressive, but would rather stimulate 
T cell-mediated immunity through the production of 
co-stimulatory molecules enhancing proliferation of 
CD4+and CD8+ T cells [29, 30]. The role of human 
TANs in perturbing immunity is poorly defined 
mechanistically, and gaps remain in understanding 
TANs plasticity and the switch between pro- and 
antitumoral effects in vitro. Further, little is known of 
the in vivo properties of TANs and whether in vitro data 
from studies in mice can be extrapolated to humans. 
Moreover, a plethora of signaling molecules, differing 
between and even within different stages of the same 
histological subtypes, are available to influence TANs. 
This is a plausible explanation for why the prognostic 
significance of CD66b+ TANs diverging according to 
histological subtypes. This is supported by the two 
predominant NSCLC histological phenotypes, SCC and 
ADC, displaying distinct differences in genomic and 
stromal heterogeneity, association to smoking, growth 
pattern and sensitivity to treatment [23], and are by 
many regarded as different entities.
Tumor infiltrating immune cells have a pivotal 
contribution in cancer progression and critically 
influences the clinical outcome of patients depending 
on density and localization of various immune cell 
subsets [31]. The analysis of the immune contexture 
in NSCLC has revealed supplementary prognostic 
ALL SCC ADC
Correlations with markers expressed in intratumoral cells
Tumor Stroma Tumor Stroma Tumor Stroma
PAR6 0.22** EMT S
CD138 0.21** IMM S
CD1a 0.20** IMM S
CD66b 0.76# 0.80# 0.66# IMM S
CSF1R 0.23# 0.25# 0.26*** 0.28# 0.23* 0.21* IMM S
CXCL16 0.25*** IMM S
FOXP3 0.21** IMM S
CD68 0.23# 0.23** 0.27# IMM S
MCSF 0.28# 0.25# 0.32# 0.32# IMM S
FOXO1A 0.28# IMM S
LDH5 0.24*** MET S
MCT1 0.23# 0.26# 0.23** 0.30# 0.28** 0.24* MET S
MCT4 0.22# 0.20*** 0.20** 0.23* 0.27** MET S
Abbreviations: CD, cluster of differentiation; SCC, squamous cell carcinoma; ADC, adenocarcinoma;ANG, angiogenesis; 
EMT, epithelial-mesenchymal transition; MET, metastasis; IMM; immunology; CAIX, Anti-Carbonic Anhydrase IX;DLL4, 
Delta ligand 4; FGFR1, Fibroblast Growth Factor Receptor 1; GLUT1, Glucose transporter 1; PHD, prolyl hydroxylase-
domain; BAD, Bcl2 Associated Death Promoter; Cyt, in cytoplasm; Nuc, in nucleus; Her, human epidermal growth factor 
receptor; MCT, monocarboxylate transporter; PGC1, Peroxisome proliferative activated receptor gamma coactivator 1; 
Ang, angiogenin; miR, micro RNA; PDGF, Platelet-derived growth factor; VEGF, Vascular endothelial growth factor; 
IGF1, Insulin like growth factor 1; PAR6, Partitioning defective 6; CXCL16, C-X-C motif ligand; FOX, forkhead 
box; MCSF, Macrophage Colony Stimulating Factor 1; CSF1R, Colony stimulating factor 1 receptor; LDH, lactate 
dehydrogenase.
*significant at p > 0.05,
**significant at p > 0.01,
***significant at p >0.001,
# significant after Bonferroni correction for multiple tests
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and predictive data which may be combined with the 
standard pathological TNM classification to form a 
TNM-Immunoscore (TNM-I) [32]. Recently, our group 
have reported stromal CD8+ and CD45RO+ TILs to 
positively associate with survival, hence being good 
candidate markers for a TNM-I in NSCLC [24, 33]. 
The effect of TILs in NSCLC is best documented in the 
SCC subgroup, while the data presented herein indicate 
that CD66b+ TANs to be a candidate in TNM-I for the 
ADC subgroup. Supplementary Figure S3 shows how 
incorporation of CD66+ TAN status could improve the 
prognostic properties of the established TNM staging 
system for NSCLC ADC patients. However, these data 
are preliminary and need to be confirmed in larger 
NSCLC ADC cohorts.
In conclusion, we observed that intratumoral 
CD66b+ TANs is both an independent positive and 
negative prognosticator in the SCC and ADC subgroup 
of NSCLC patients, respectively. While CD8+/CD3+/
CD45RO+ TILs seem to be pivotal for the establishment 
of a TNM-I for NSCLC SCC patients, CD66b+ TANs 
may prove an appropriate choice for ADC patients.
MATERIALS AND METHODS
Patients and ethical clearance
An unselected population of 536 patients with 
surgically resected stage I-IIIA NSCLC from the 
University Hospital of North-Norway and Nordland 
Central Hospital from 1990-2010 were included in this 
study. Of 536 patients, 509 were involved in survival 
analysis, while the remaining cases are highlighted as 
missing due to poor tissue quality and unscorable cores.
For the N+ patients, the total number (n=172) 
constitutes all patients in the cohort with N+ disease. 
Of these 55 were either missing due to bad or missing 
cores or due the fact that LN tissue was not available in 
the archival tissue. Both study populations are described 
previously by our group [24, 25].
The study was approved by the Regional Committee 
for Medical and Health Research Ethics (Northern 
Norway, UNN: protocol ID: 2011/2503). Data collection 
and storing of the clinical database were approved by the 
National Data Inspection Board. The study instructions 
for biomarker expression, clinicopathological features 
and survival data is reported according to the REMARK 
guidelines [34].
Tissue micro-array construction and 
Immunohistochemistry
All tissue samples were reviewed by two 
experienced pathologists (ER.LTB). The most 
representative areas was marked on the hemotoxylin and 
eosin (H&E) slide and sampled for tissue micro-array 
(TMA) blocks. The TMAs were assembled using a tissue-
arraying instrument (Beecher Instruments, Silver Springs, 
MD, USA). The methodology has previously been 
explained [35]. Briefly, four 0.6 mm cores were sampled 
for each patient: two from central tumor epithelium and 
two from tumor stroma.
Multiplexed Immunohistochemistry
Triple IHC staining was carried out sequentially 
using the Discovery-Ultra automated immunostainer 
(Ventana Medical Systems, Tucson, AZ). Deparaffinization 
and on-board antigen retrieval were performed for 32 
minutes at approximately 100°C with CC1 reagent, which 
is an EDTA-based proprietary Ventana solution (pH 
8.0–8.5). CD66b mouse monoclonal antibody (#555723, 
clone:G10F5, BD Biosciences, dilution 1/400) was 
applied and incubated for 32 min and amplified for 4 
min, followed by an ultraWash step to wash off excess 
antibody. Antibody denaturation for 8 minutes at 90°C 
was performed to ensure that the first primary antibody 
was completely inactivated before applying the second 
antibody. The pre-diluted CD34 mouse monoclonal 
antibody (#790-2927, Ventana, Clone: QBEnd/10) was 
then applied as a second primary antibody and was 
incubated for 32 minutes, and then washed, followed 
by denaturation. In the last sequence pre-diluted mouse 
monoclonal anti-pan keratin (CK) (#760-2135, Ventana, 
Clone: AE1/AE3/PCK26) was applied with 16 min 
incubation. The primary antibodies CD66b, CD34 and 
pan CK were visualized using Ventana DAB, Purple, 
Yellow detection kits respectively with 32 min incubation 
time for DAB, 16 min for purple and 1 hour for yellow 
chromogens. Finally, the slides were counterstained with 
hematoxylin and bluing reagent.
All triple stained sections were compared with the 
corresponding single stained section slide. Three different 
controls for our staining method were applied: 1) A blank 
control by omission of the primary antibody in every 
sequence of staining, 2) control staining of the sections 
with an isotype-matched control antibody without the 
primary antibody and 3) multiple organ TMAs as positive 
and negative tissue controls to verify the specificity of the 
staining for every staining procedure
Scoring of immunohistochemistry
Two pathologists (LTB, ER) established a semi-
quantitative score. Pan-keratin identified normal and 
malignant epithelium, while CD34 differentiated intra- 
and extra-vascular CD66b+ TANs.
The TMA slides were scored by two observers 
(MR, EEP) for intratumoral (primary tumors and lymph 
nodes) and stromal (primary tumors) CD66b+ TANs. 
A four-tiered scale with the following levels: 0 ≤ 1, 1 = 
1-5, 2 = 6-15, 3 >15 for both the tumor epithelial and 
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stromal compartments was used. Intravascular CD66b+ 
TANs, necrotic and pre-necrotic areas were disregarded. 
The method used for pathological evaluation of CD66b+ 
neutrophil density in tumor and stromal compartments 
is presented in Figure 1A. Representative images of 
triple staining with low and high densities are shown in 
Figure 1B.
For statistical analysis, dichotomization was done 
and high presence defined as >5 CD66b+ neutrophils 
(score 2 or 3).
TMA Validation
Whole-tissue section slides of 20 patients were 
evaluated for tumor heterogeneity with corresponding 
TMA cores. The selected cases was from different 
histological and pathological stages with following detail: 
10 specimen of ADC (5 tStage I, 5 tStage III), 10 specimen 
of SCC (5 tStage I, 5 tStage III). The applied staining 
procedure for whole-tissue section was the same as for 
TMA slides. Heterogeneity between paired TMA core and 
whole tissue was low and a significant concordance was 
observed for TAN density intratumorally (paired T-test 
correlation= 0.91; p = <0.001).
Statistical methods
All data analyses were conducted in RStudio with 
R version 3.2.2 utilizing the packages survival, gridExtra, 
car, Hmisc, irr and ggplot2.
IHC scores were compared for interobserver 
reliability using a two-way random effects model with an 
absolute agreement definition and Cohen’s kappa-statistics 
with equal weights. The intraclass correlation coefficient 
and Cohen’s kappa were obtained from these results.
The Chi-square and Fischer’s Exact tests were used 
to examine the association between marker expression and 
clinicopathological variables. Spearman`s rank-correlation 
was used to examine the associations between marker 
expressions. Due to the large number variables analyzed 
in the correlation analyses, Bonferroni corrections were 
conducted for these analyses.
Univariate survival analyses, were done using the 
Kaplan-Meier method and statistical difference between 
survival curves assessed by the log-rank test. DSS, DFS 
and OS were used as end-points. Multivariable analysis, 
using the Cox proportional hazards model, was carried out 
to assess the independent value of pretreatment variables 
in the presence of other variables. Only variables with P 
< 0.25 from the univariate analyses or otherwise deemed 
important were explored in multivariable analyses. The 
significance level used for survival analyses was P < 0.05.
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